168 related articles for article (PubMed ID: 10838667)
1. Development of a polynucleotide vaccine from melanoma antigen recognized by T cells-1 and recombinant protein from melanoma antigen recognized by T cells-1 for melanoma vaccine clinical trials.
Lee SW; Li H; Strong TV; Moore SE; Conry RM
J Immunother; 2000; 23(3):379-86. PubMed ID: 10838667
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse.
Triozzi PL; Aldrich W; Allen KO; Carlisle RR; LoBuglio AF; Conry RM
J Immunother; 2005; 28(4):382-8. PubMed ID: 16000957
[TBL] [Abstract][Full Text] [Related]
3. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
4. Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1.
Kawakami Y; Battles JK; Kobayashi T; Ennis W; Wang X; Tupesis JP; Marincola FM; Robbins PF; Hearing VJ; Gonda MA; Rosenberg SA
J Immunol Methods; 1997 Mar; 202(1):13-25. PubMed ID: 9075767
[TBL] [Abstract][Full Text] [Related]
5. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.
Rosenberg SA; Zhai Y; Yang JC; Schwartzentruber DJ; Hwu P; Marincola FM; Topalian SL; Restifo NP; Seipp CA; Einhorn JH; Roberts B; White DE
J Natl Cancer Inst; 1998 Dec; 90(24):1894-900. PubMed ID: 9862627
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
Butterfield LH; Comin-Anduix B; Vujanovic L; Lee Y; Dissette VB; Yang JQ; Vu HT; Seja E; Oseguera DK; Potter DM; Glaspy JA; Economou JS; Ribas A
J Immunother; 2008 Apr; 31(3):294-309. PubMed ID: 18317358
[TBL] [Abstract][Full Text] [Related]
7. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1.
Schneider J; Brichard V; Boon T; Meyer zum Büschenfelde KH; Wölfel T
Int J Cancer; 1998 Jan; 75(3):451-8. PubMed ID: 9455808
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A
J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391
[TBL] [Abstract][Full Text] [Related]
9. KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity.
Skoberne M; Yewdall A; Bahjat KS; Godefroy E; Lauer P; Lemmens E; Liu W; Luckett W; Leong M; Dubensky TW; Brockstedt DG; Bhardwaj N
J Clin Invest; 2008 Dec; 118(12):3990-4001. PubMed ID: 19033668
[TBL] [Abstract][Full Text] [Related]
10. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.
Schütz A; Oertli D; Marti WR; Noppen C; Padovan E; Spagnoli GC; Heberer M; Zajac P
Cancer Gene Ther; 2001 Sep; 8(9):655-61. PubMed ID: 11593334
[TBL] [Abstract][Full Text] [Related]
12. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells.
Zarour HM; Kirkwood JM; Kierstead LS; Herr W; Brusic V; Slingluff CL; Sidney J; Sette A; Storkus WJ
Proc Natl Acad Sci U S A; 2000 Jan; 97(1):400-5. PubMed ID: 10618430
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine.
Reynolds SR; Oratz R; Shapiro RL; Hao P; Yun Z; Fotino M; Vukmanović S; Bystryn JC
Int J Cancer; 1997 Sep; 72(6):972-6. PubMed ID: 9378560
[TBL] [Abstract][Full Text] [Related]
14. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
[TBL] [Abstract][Full Text] [Related]
15. Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity.
Rivoltini L; Loftus DJ; Squarcina P; Castelli C; Rini F; Arienti F; Belli F; Marincola FM; Geisler C; Borsatti A; Appella E; Parmiani G
Crit Rev Immunol; 1998; 18(1-2):55-63. PubMed ID: 9419448
[TBL] [Abstract][Full Text] [Related]
16. Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35).
Loftus DJ; Castelli C; Clay TM; Squarcina P; Marincola FM; Nishimura MI; Parmiani G; Appella E; Rivoltini L
J Exp Med; 1996 Aug; 184(2):647-57. PubMed ID: 8760818
[TBL] [Abstract][Full Text] [Related]
17. Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis.
Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
J Immunol Methods; 2000 Oct; 244(1-2):59-67. PubMed ID: 11033019
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
[TBL] [Abstract][Full Text] [Related]
19. Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization.
Surman DR; Irvine KR; Shulman EP; Allweis TM; Rosenberg SA; Restifo NP
J Immunol Methods; 1998 May; 214(1-2):51-62. PubMed ID: 9692858
[TBL] [Abstract][Full Text] [Related]
20. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
